BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (ONC)
CUSIP: 07725L102
Q2 2017 13F Holders as of 30 Jun 2017
- Type / Class
- Equity / Ordinary Shares, par value $0.0001 per share
- Shares outstanding
- 1,448,978,913
- Total 13F shares
- 20,400,002
- Share change
- +2,792,255
- Total reported value
- $917,998,000
- Price per share
- $45.00
- Number of holders
- 57
- Value change
- +$131,190,803
- Number of buys
- 33
- Number of sells
- 26
Quarterly Holders Quick Answers
What is CUSIP 07725L102?
CUSIP 07725L102 identifies ONC - BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 07725L102:
Top shareholders of ONC - BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
0.28%
|
3,987,748
|
$145,991,000 | — | 31 Mar 2017 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.25%
|
3,673,175
|
$134,475,000 | — | 31 Mar 2017 | |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. |
13F
|
Company |
0.09%
|
1,364,820
|
$49,966,000 | — | 31 Mar 2017 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.09%
|
1,256,825
|
$46,013,000 | — | 31 Mar 2017 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.07%
|
1,035,990
|
$37,928,000 | — | 31 Mar 2017 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.06%
|
903,700
|
$33,084,000 | — | 31 Mar 2017 | |
| Boxer Capital, LLC |
13F
|
Company |
0.06%
|
850,000
|
$31,119,000 | — | 31 Mar 2017 | |
| BROWN ADVISORY INC |
13F
|
Company |
0.03%
|
479,351
|
$17,549,000 | — | 31 Mar 2017 | |
| Temasek Holdings (Private) Ltd |
13F
|
Company |
0.03%
|
380,000
|
$13,912,000 | — | 31 Mar 2017 | |
| Artal Group S.A. |
13F
|
Company |
0.03%
|
363,286
|
$13,300,000 | — | 31 Mar 2017 | |
| Myriad Asset Management Ltd. |
13F
|
Company |
0.02%
|
330,685
|
$12,106,000 | — | 31 Mar 2017 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.02%
|
265,000
|
$9,702,000 | — | 31 Mar 2017 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.02%
|
264,615
|
$9,687,000 | — | 31 Mar 2017 | |
| Prince Street Capital Management LLC |
13F
|
Company |
0.02%
|
246,900
|
$9,039,000 | — | 31 Mar 2017 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
0.02%
|
240,000
|
$8,786,000 | — | 31 Mar 2017 | |
| Fosun International Ltd |
13F
|
Company |
0.01%
|
214,679
|
$7,859,000 | — | 31 Mar 2017 | |
| Ariose Capital Management Ltd |
13F
|
Company |
0.01%
|
198,609
|
$7,271,000 | — | 31 Mar 2017 | |
| QVT Financial LP |
13F
|
Company |
0.01%
|
170,000
|
$6,224,000 | — | 31 Mar 2017 | |
| CONNING INC. |
13F
|
Company |
0.01%
|
161,250
|
$5,903,000 | — | 31 Mar 2017 | |
| S.c.a. Candriam |
13F
|
Individual |
0.01%
|
115,000
|
$4,210,000 | — | 31 Mar 2017 | |
| Polar Capital LLP |
13F
|
Company |
0.01%
|
100,000
|
$3,661,000 | — | 31 Mar 2017 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.01%
|
92,633
|
$3,391,000 | — | 31 Mar 2017 | |
| Tekla Capital Management LLC |
13F
|
Company |
0.01%
|
87,531
|
$3,205,000 | — | 31 Mar 2017 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.01%
|
81,231
|
$2,974,000 | — | 31 Mar 2017 | |
| BAILLIE GIFFORD & CO |
13F
|
Company |
0%
|
70,865
|
$2,594,000 | — | 31 Mar 2017 | |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC |
13F
|
Company |
0%
|
66,041
|
$2,419,000 | — | 31 Mar 2017 | |
| University Of Notre Dame du Lac |
13F
|
Individual |
0%
|
63,211
|
$2,314,000 | — | 31 Mar 2017 | |
| EMORY UNIVERSITY |
13F
|
Company |
0%
|
57,654
|
$2,111,000 | — | 31 Mar 2017 | |
| OppenheimerFunds, Inc. |
13F
|
Company |
0%
|
56,977
|
$2,086,000 | — | 31 Mar 2017 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0%
|
47,831
|
$1,751,000 | — | 31 Mar 2017 | |
| State of New Jersey Common Pension Fund D |
13F
|
Company |
0%
|
45,987
|
$1,684,000 | — | 31 Mar 2017 | |
| Greenwoods Asset Management Ltd |
13F
|
Company |
0%
|
36,000
|
$1,318,000 | — | 31 Mar 2017 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0%
|
32,563
|
$1,191,000 | — | 31 Mar 2017 | |
| STATE STREET CORP |
13F
|
Company |
0%
|
31,985
|
$1,171,000 | — | 31 Mar 2017 | |
| Vident Investment Advisory, LLC |
13F
|
Company |
0%
|
29,746
|
$1,089,000 | — | 31 Mar 2017 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0%
|
29,273
|
$1,072,000 | — | 31 Mar 2017 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0%
|
26,668
|
$976,000 | — | 31 Mar 2017 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
20,199
|
$740,000 | — | 31 Mar 2017 | |
| GUGGENHEIM CAPITAL LLC |
13F
|
Company |
0%
|
20,050
|
$735,000 | — | 31 Mar 2017 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0%
|
18,421
|
$674,000 | — | 31 Mar 2017 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0%
|
14,061
|
$515,000 | — | 31 Mar 2017 | |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC |
13F
|
Company |
0%
|
10,796
|
$395,000 | — | 31 Mar 2017 | |
| ProShare Advisors LLC |
13F
|
Company |
0%
|
9,872
|
$361,000 | — | 31 Mar 2017 | |
| VIRTUS ADVISERS, LLC |
13F
|
Company |
0%
|
9,669
|
$354,000 | — | 31 Mar 2017 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0%
|
9,428
|
$345,000 | — | 31 Mar 2017 | |
| Airain ltd |
13F
|
Company |
0%
|
8,754
|
$320,000 | — | 31 Mar 2017 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0%
|
6,500
|
$238,000 | — | 31 Mar 2017 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
5,795
|
$212,000 | — | 31 Mar 2017 | |
| Legal & General Group Plc |
13F
|
Company |
0%
|
5,000
|
$183,000 | — | 31 Mar 2017 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0%
|
4,482
|
$164,000 | — | 31 Mar 2017 |
Institutional Holders of BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (ONC) as of Q2 2017
As of 30 Jun 2017,
BeOne Medicines Ltd. - Ordinary Shares, par value $0.0001 per share (ONC) was held by
57 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,400,002 shares.
The largest 10 holders included
FMR LLC, Hillhouse Capital Management, Ltd., BAKER BROS. ADVISORS LP, WELLINGTON MANAGEMENT GROUP LLP, ORBIMED ADVISORS LLC, PRICE T ROWE ASSOCIATES INC /MD/, OppenheimerFunds, Inc., Boxer Capital, LLC, BROWN ADVISORY INC, and Artal Group S.A..
This page lists
57
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2017 vs Q1 2017 Across Filers
Q1 2017 holders
54
Q2 2017 holders
57
Holder diff
3
| Investor | Q1 2017 Shares | Q2 2017 Shares | Share Diff | Share Chg % | Q1 2017 Value $ | Q2 2017 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.